Share price · SNY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SNY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+2.7%
- 30 Oct 2026+2.8%
- 20 Oct 2026+4.6%
- 24 Sep 2026-1.7%
Nothing announced by SNY that day or the session before.
- 1 Jul 2026-2.4%
- 4 May 2026-5.9%
- Day beforeArrowhead Pharmaceuticals: Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)ARWR +2.1%
- 19 Mar 2026+3.7%
Nothing announced by SNY that day or the session before.
- 19 Feb 2026+2.7%
Nothing announced by SNY that day or the session before.
- 13 Feb 2026-2.2%
- 12 Feb 2026-4.5%
Share of unusual movement by asset
For each asset, the share of SNY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(63 total)
| Target & Modality | |||
|---|---|---|---|
Aficamten(Myqorzo) | Approved | Cardiac myosin (inhibitor)Small molecule | Hypertrophic Cardiomyopathy |
Agalsidase beta(Fabrazyme) | Approved | Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic | Fabry Disease |
| Approved | CD52Monoclonal antibody | Multiple SclerosisChronic Lymphocytic Leukemia | |
Alirocumab(Praluent) | Approved | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia |
| Approved | Rho-associated kinase (ROCK, pan)Small molecule | Graft-versus-Host Disease Chronic Graft-versus-Host Disease | |
Docetaxel(Taxotere) | Approved | Microtubules (tubulin)Small molecule | Non-Small Cell Lung CancerBreast CancerMetastatic Castration-Resistant Prostate CancerGastric CancerHead and Neck Squamous Cell CarcinomaProstate Cancer HR+/HER2- Metastatic Breast Cancer |
dupilumab(Dupixent) | Approved | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous UrticariaPrurigo NodularisEosinophilic Esophagitis |
Fitusiran(Qfitlia) | Approved | Antithrombin (SERPINC1) mRNARNA / oligonucleotide | Hemophilia Hemophilia A and B |
glimepiride(Amaryl) | Approved | Sulfonylurea receptor (SUR1)Small molecule | Type 2 Diabetes |
Glyburide(DiaBeta) | Approved | Sulfonylurea receptor (SUR1)Small molecule | Type 2 Diabetes |
insulin glargine(Lantus) | Approved | Insulin receptor (basal)Peptide | Type 2 DiabetesType 1 Diabetes |
| Approved | Insulin receptor (basal)Peptide | Type 2 DiabetesType 1 Diabetes | |
insulin glulisine(Apidra) | Approved | Insulin receptorPeptide | Type 2 DiabetesType 1 Diabetes |
| Approved | CD38Monoclonal antibody | Multiple Myeloma | |
Laronidase(ALDURAZYME) | Approved | Alpha-L-iduronidase (IDUA)Protein / enzyme therapeutic | Mucopolysaccharidosis Type I |
Discontinued programmes (6)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(68 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
November 2026 (1)
What to watch
December 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (22)
January 2027 (1)
What to watch
February 2027 (2)
March 2027 (2)
April 2027 (5)
May 2027 (2)
What to watch
June 2027 (2)
What to watch
July 2027 (3)
September 2027 (2)
What to watch
October 2027 (2)
November 2027 (1)
What to watch
2028 (16)
March 2028 (2)
May 2028 (3)
June 2028 (3)
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (3)
October 2028 (1)
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (16)
January 2029 (1)
What to watch
February 2029 (2)
What to watch
March 2029 (2)
April 2029 (1)
What to watch
May 2029 (1)
June 2029 (1)
July 2029 (1)
August 2029 (3)
September 2029 (1)
What to watch
October 2029 (1)
What to watch
2030 (3)
2031 (3)
2032 (1)
September 2032 (1)
What to watch
2033 (1)
2035 (1)
May 2035 (1)
What to watch
Regulatory and conference events
(35)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 34 past events are shown.
Financial reports
Quarterly & interim (8)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $12.0B | $2.0B | $6.3B | — | report ↗ |
View 7 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | $13.2B | $2.7B | $9.0B | — | report ↗ |
| 2025-Q3 | $14.5B | $2.1B | $10.4B | — | report ↗ |
| 2025-Q2 | $11.3B | $2.2B | $18.0B | — | report ↗ |
| 2025-Q1 | $10.4B | $1.9B | $8.6B | — | report ↗ |
| 2024-Q4 | $11.3B | $2.4B | $7.7B | — | report ↗ |
| 2024-Q3 | $14.8B | $2.0B | — | — | report ↗ |
| 2024-Q2 | $11.6B | $1.8B | $7.3B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $49.5B | $8.9B | $9.0B | — | report ↗ |
Sanofi reported FY2025 revenue of $49,451.93M, up 11.2% YoY, with R&D spend of $8,889.24M, up 11.1% YoY. Cash and equivalents stood at $9,002.03M, and the company recorded net income of $8,899.44M. No analyst expectations comparison was provided.
In business developments, Dupixent received approval in Japan as the first targeted medicine for adults with moderate-to-severe bullous pemphigoid, based on the LIBERTY-BP-ADEPT phase 2/3 study showing 18% of Dupixent patients achieved sustained disease remission versus 4% on placebo (p=0.0250); treatment-related adverse events occurred in 26% of Dupixent patients and 15% of placebo patients, with conjunctivitis the most common (4%). This is Dupixent’s seventh approved indication in Japan, and phase 3 studies continue in chronic pruritus of unknown origin and lichen simplex chronicus.
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 731 reporting institutions held 209.6M shares ($9.8B, 8.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Dodge & Cox | 29,504,632 | $1.4B |
| 2 | MORGAN STANLEY | 12,511,867 | $602.8M |
| 3 | Fisher Asset Management, LLC | 11,442,163 | $551.3M |
| 4 | BANK OF AMERICA CORP /DE/ | 9,484,350 | $457.0M |
| 5 | FRANKLIN RESOURCES INC | 7,165,193 | $345.2M |
| 6 | Invesco Ltd. | 6,621,539 | $319.0M |
| 7 | BARROW HANLEY MEWHINNEY & STRAUSS LLC | 5,887,466 | $283.7M |
| 8 | JPMORGAN CHASE & CO | 5,600,731 | $261.7M |
| 9 | Mondrian Investment Partners LTD | 5,040,065 | $242.8M |
| 10 | FEDERATED HERMES, INC. | 4,754,359 | $229.1M |
| 11 | FMR LLC | 4,010,161 | $193.2M |
| 12 | ENVESTNET ASSET MANAGEMENT INC | 3,861,894 | $186.1M |
| 13 | RAYMOND JAMES FINANCIAL INC | 3,812,745 | $183.7M |
| 14 | BRANDES INVESTMENT PARTNERS, LP | 3,723,100 | $179.4M |
| 15 | Boston Partners | 3,599,284 | $173.4M |